PeerView Gastroenterology CME/CNE/CPE Audio Podcast PeerView Press

Go online to PeerView.com/QBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC-accredited video activity, Josep Tabernero, MD, PhD, gives his perspective on the latest evidence on novel HER2-targeted and other molecular-directed therapies in gastric cancer. Hear about recent data presented on gastric cancer and how precision medicine may improve gastric cancer patient care. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

Go online to PeerView.com/VJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directions. Upon completion of this activity, participants should be better able to: Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, and non–small cell lung cancers, Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or ERBB2-mutant cancers, Identify novel approaches to overcome mechanisms of resistance to HER2-targeted therapies, Integrate the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or ERBB2-mutant breast, gastric, colorectal, and non–small cell lung cancers, either in the context of clinical practice or through clinical trial participation.

Go online to PeerView.com/VBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC-accredited video activity, Josep Tabernero, MD, PhD; Geoffrey Ku, MD; and Kohei Shitara, MD, synthesize the latest data of emerging and available novel therapies and consider the future of gastric cancer care. These experts also examine best practices for testing biomarkers such as HER2, PD-L1, and MSI, and provide guidance on integrating scientific advances and novel therapeutics into sound, evidence-based management strategies to improve outcomes for patients with gastric cancer. Upon completion of this activity, participants should be better able to: Review the biologic rationale for targeting molecular signatures of gastric cancer, such as HER2 or PD-L1 overexpression, Examine expert and guideline-based biomarker testing recommendations in gastric cancer that can guide optimal treatment selection, Assess the latest safety and efficacy evidence of novel therapeutics for gastric cancer, such as checkpoint inhibitors, cytotoxic agents, and HER2-directed antibody-drug conjugates, Develop safe and effective validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

Go online to PeerView.com/BBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Targeted therapies have had a beneficial role in the advanced gastric or GEJ cancer setting, and several novel strategies of combining targeted therapy with immunotherapy are evolving the treatment landscape. While medicine continues to scientifically advance, the holistic care of patients with gastric/GEJ cancers is becoming more complex, and factors such as symptom management, psychological support, and nutritional considerations, in addition to effective treatment selection, need to be considered to offer the best clinical and quality of life outcomes to patients. This three-part educational activity offers learners an exclusive look at how science and care merge in the clinic to enhance the multidisciplinary, multidirectional management of patients with gastric/GEJ cancers. Upon completion of this activity, participants will be able to: Summarize clinical evidence on established targeted therapies, such as antiangiogenic agents, and emerging combination strategies, such as with checkpoint inhibitors, for advanced gastric or gastroesophageal junction (GEJ) cancers, Select appropriate second-line targeted therapies based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric/GEJ cancers who have progressed following first-line chemotherapy, Develop a holistic treatment plan that addresses nutrition/diet concerns, emotional distress, treatment-related adverse events, and risk of disease progression, among other issues, with a multidisciplinary and interprofessional team of clinicians who care for patients with advanced gastric/GEJ cancers.

Go online to PeerView.com/DWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, antiangiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC. Upon completion of this activity, participants should be better able to: Review pivotal clinical evidence on newly available systemic treatment options, including multikinase inhibitors, antiangiogenic agents, and checkpoint inhibitors, for newly diagnosed and previously treated patients with advanced HCC, Examine the potential role of combination systemic therapy approaches (eg, dual immune checkpoint blockade, immunotherapy plus targeted therapy) for advanced HCC, Assess emerging evidence on novel multimodal approaches for intermediate- and advanced-stage HCC, Develop optimal multidisciplinary treatment plans based on available evidence, patient- and disease-related factors, and recommendations on timely transitions from locoregional to systemic options for patients with intermediate or advanced HCC.

Go online to PeerView.com/NPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic visceral acid sphingomyelinase deficiency (ASMD), also referred to as Niemann-Pick disease type B, is a rare and progressive autosomal recessive lysosomal storage disorder that causes progressive accumulation of sphingomyelin and other lipids in tissues throughout the body and is associated with significant morbidity and reduced life expectancy. The diagnosis of chronic visceral ASMD is often delayed by months or years, because its complex signs and symptoms overlap with other diseases. In this activity, leading experts review current consensus recommendations for the diagnosis of ASMD in pediatric and adult patients. The faculty also review the latest safety, efficacy, and tolerability data on emerging therapies and explore patient cases to offer practical strategies on how to optimally manage patients with chronic visceral ASMD. Upon completion of this activity, participants should be better able to: Diagnose individuals with ASMD through the application of recent consensus recommendations, Cite available efficacy, safety, and tolerability data on emerging therapeutic modalities for the treatment of patients with ASMD, Examine the potential impact that ongoing clinical trials of emerging therapeutic approaches may have on the future treatment of patients with ASMD.